BioArctic AB (BRCTF) reports a surge in revenue and profit, driven by strategic alliances and expanding market presence, while addressing future challenges.

Eisai has put direct-to-consumer (DTC) advertising at the heart of its ongoing efforts to expand demand for Leqembi. | Eisai ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

EMA’s reluctance in approving drugs for the condition underscores Europe’s prioritisation of long-term safety over rapid ...

U.S. health officials have endorsed the first blood test that can help diagnose Alzheimer’s. The test would help identify ...

Investing.com -- Shares in BioArctic AB (ST: BIOAb) rose more than 4% on Wednesday after the company posted ...

Hi, it’s Amber in Hong Kong. Across the strait in Taiwan, breakthrough Alzheimer’s drugs are finally becoming available but ...

The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the ...

Leqembi (lecanemab-irmb) is a prescription drug that’s used to treat Alzheimer’s disease. The drug comes as a liquid that’s given as an infusion into a vein. It’s usually given once every ...

Biotech company Biogen (NASDAQ:BIIB) in Q1 CY2025, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was 1.9% above analysts’ consensus estimates. Is now the ...

The Food and Drug Administration has cleared Fujirebio Diagnostics’ blood test to diagnose Alzheimer’s disease, the regulator ...